Inhibitory effects of cardiotonic pills on platelet function in dogs fed a high-fat diet

Lei Zhang1, Jun Zheng, Hui-Min Li

  • 1Department of Cardiology, Tianjin 254th Hospital, Affiliated Hospital of the Medical College of Nankai University, China. zhanglei254@hotmail.com

Insights

Cardiotonic pills effectively reduced platelet hyperactivity and improved metabolic health in insulin-resistant dogs. This herbal component demonstrated significant antioxidative and lipid-lowering effects, surpassing aspirin in inhibiting platelet function.

Area of Science:

  • Metabolic disorders and cardiovascular health
  • Pharmacology and herbal medicine
  • Platelet biology and thrombosis

Background:

  • Insulin resistance and metabolic disorders are linked to heightened platelet activity.
  • Oxidative stress is a key driver of persistent platelet activation in these conditions.
  • Platelet hyperactivity contributes to cardiovascular complications in metabolic diseases.

Purpose of the Study:

  • To investigate the inhibitory effects of cardiotonic pills on platelet function in a canine model of insulin resistance.
  • To evaluate the impact of cardiotonic pills on metabolic parameters and oxidative stress.
  • To compare the efficacy of cardiotonic pills with aspirin in modulating platelet activity.

Main Methods:

  • Induction of insulin resistance in dogs via a 6-month high-fat diet.
  • Administration of aspirin or cardiotonic pills to insulin-resistant dogs for 4 months.
  • Assessment of metabolic parameters, oxidative stress markers, and platelet function (aggregation, adhesion molecules, calcium concentration).

Main Results:

  • High-fat feeding induced obesity, dyslipidemia, oxidative stress, and insulin resistance, accompanied by platelet hyperactivity.
  • Cardiotonic pills exhibited significant antioxidant activity and lipid-lowering effects.
  • Both aspirin and cardiotonic pills reversed platelet hypersensitivity, with cardiotonic pills showing a more pronounced inhibitory effect on platelet aggregation and adhesion molecule expression.

Conclusions:

  • Cardiotonic pills effectively inhibit platelet hyperfunction in insulin-resistant dogs.
  • The anti-platelet effects of cardiotonic pills are likely mediated by their antioxidative properties and metabolic control capabilities.
  • Cardiotonic pills represent a potential therapeutic agent for managing platelet dysfunction in metabolic disorders.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...